NO3221486T3 - - Google Patents
Info
- Publication number
- NO3221486T3 NO3221486T3 NO15775410A NO15775410A NO3221486T3 NO 3221486 T3 NO3221486 T3 NO 3221486T3 NO 15775410 A NO15775410 A NO 15775410A NO 15775410 A NO15775410 A NO 15775410A NO 3221486 T3 NO3221486 T3 NO 3221486T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916827P | 2013-12-17 | 2013-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3221486T3 true NO3221486T3 (de) | 2018-09-08 |
Family
ID=52355185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15775410A NO3221486T3 (de) | 2013-12-17 | 2015-10-02 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9776964B2 (de) |
| EP (1) | EP3083562B1 (de) |
| JP (1) | JP6212644B2 (de) |
| KR (1) | KR101807981B1 (de) |
| CN (1) | CN105793242B (de) |
| AU (1) | AU2014366361B2 (de) |
| BR (1) | BR112016011016A8 (de) |
| CA (1) | CA2928593A1 (de) |
| CY (1) | CY1119583T1 (de) |
| DK (1) | DK3083562T3 (de) |
| EA (1) | EA028921B1 (de) |
| ES (1) | ES2651858T3 (de) |
| HR (1) | HRP20171850T1 (de) |
| HU (1) | HUE035698T2 (de) |
| LT (1) | LT3083562T (de) |
| ME (1) | ME02896B (de) |
| MX (1) | MX2016007566A (de) |
| NO (1) | NO3221486T3 (de) |
| PL (1) | PL3083562T3 (de) |
| PT (1) | PT3083562T (de) |
| RS (1) | RS56615B1 (de) |
| SI (1) | SI3083562T1 (de) |
| WO (1) | WO2015094902A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN110621667A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 嘧啶衍生物 |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| PL3625228T3 (pl) | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| EP3625224B1 (de) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituierte indolderivate |
| CN109970625B (zh) * | 2017-12-28 | 2021-02-26 | 新发药业有限公司 | 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法 |
| US20220324803A1 (en) * | 2019-06-11 | 2022-10-13 | Teon Therapeutics, Inc. | Prostaglandin e2 receptor 4 antagonists and uses thereof |
| EP3885339A1 (de) * | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Verfahren zur herstellung von (r)-4-(1-(6-(4-(trifluormethyl)benzyl)-6-azaspiro[2.5]octan-5-carboxamido)-cyclopropyl)benzoesäure oder eines salzes davon |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| CN112608271A (zh) * | 2020-11-26 | 2021-04-06 | 安润医药科技（苏州）有限公司 | 酰胺衍生物及其在制备ep4受体拮抗剂中的应用 |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
| CN117164507A (zh) * | 2023-05-26 | 2023-12-05 | 康化（上海）新药研发有限公司 | 一种阿加曲班杂质(2r,4r)-4-甲基-2-哌啶甲酸的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| WO2003077910A1 (en) | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| CN1856490A (zh) * | 2003-07-28 | 2006-11-01 | 詹森药业有限公司 | 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用 |
| CN1867551B (zh) * | 2003-09-03 | 2013-09-11 | 拉夸里亚创药株式会社 | 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物 |
| CN1950333A (zh) | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| AP2006003769A0 (en) * | 2004-05-04 | 2006-10-31 | Pfizer | Ortho substituted aryl or heteroaryl amide compounds |
| EP2013169B1 (de) | 2006-04-24 | 2012-08-22 | Merck Canada Inc. | Indolamidderivate als antagonisten des ep4-rezeptors |
| EP2035376B1 (de) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indolinamidderivate als ep4-rezeptorliganden |
| JP5408434B2 (ja) * | 2007-07-03 | 2014-02-05 | アステラス製薬株式会社 | アミド化合物 |
| EP2565191B1 (de) * | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarbonsäure-Derivate als EP4-Rezeptor Antagonisten verwendbar für die Behandlung von chronischem Nierenversagen oder diabetischer Nephropathie |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| ES2600355T3 (es) | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
| EP2729141B1 (de) | 2011-07-04 | 2015-12-09 | Rottapharm Biotech S.r.l. | Cyclische aminderivate als ep4 -rezeptoragonisten |
| EP2729445B1 (de) * | 2011-07-04 | 2015-10-21 | Rottapharm Biotech S.r.l. | Cyclische aminderivate als ep4 -rezeptorantagonisten |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) * | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
-
2014
- 2014-12-11 ME MEP-2017-238A patent/ME02896B/de unknown
- 2014-12-11 JP JP2016538744A patent/JP6212644B2/ja not_active Expired - Fee Related
- 2014-12-11 ES ES14827907.8T patent/ES2651858T3/es active Active
- 2014-12-11 BR BR112016011016A patent/BR112016011016A8/pt not_active IP Right Cessation
- 2014-12-11 HR HRP20171850TT patent/HRP20171850T1/hr unknown
- 2014-12-11 CN CN201480068170.1A patent/CN105793242B/zh not_active Expired - Fee Related
- 2014-12-11 EA EA201690894A patent/EA028921B1/ru not_active IP Right Cessation
- 2014-12-11 KR KR1020167015741A patent/KR101807981B1/ko not_active Expired - Fee Related
- 2014-12-11 EP EP14827907.8A patent/EP3083562B1/de active Active
- 2014-12-11 CA CA2928593A patent/CA2928593A1/en not_active Abandoned
- 2014-12-11 RS RS20171227A patent/RS56615B1/sr unknown
- 2014-12-11 AU AU2014366361A patent/AU2014366361B2/en not_active Ceased
- 2014-12-11 US US15/030,888 patent/US9776964B2/en not_active Expired - Fee Related
- 2014-12-11 WO PCT/US2014/069743 patent/WO2015094902A1/en not_active Ceased
- 2014-12-11 LT LTEP14827907.8T patent/LT3083562T/lt unknown
- 2014-12-11 MX MX2016007566A patent/MX2016007566A/es unknown
- 2014-12-11 PL PL14827907T patent/PL3083562T3/pl unknown
- 2014-12-11 PT PT148279078T patent/PT3083562T/pt unknown
- 2014-12-11 SI SI201430434T patent/SI3083562T1/sl unknown
- 2014-12-11 HU HUE14827907A patent/HUE035698T2/en unknown
- 2014-12-11 DK DK14827907.8T patent/DK3083562T3/da active
-
2015
- 2015-10-02 NO NO15775410A patent/NO3221486T3/no unknown
-
2017
- 2017-11-09 CY CY20171101176T patent/CY1119583T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS56615B1 (sr) | 2018-02-28 |
| HUE035698T2 (en) | 2018-05-28 |
| JP2016540007A (ja) | 2016-12-22 |
| HRP20171850T1 (hr) | 2018-01-12 |
| AU2014366361A1 (en) | 2016-05-19 |
| KR20160084467A (ko) | 2016-07-13 |
| PT3083562T (pt) | 2017-12-13 |
| US20160272585A1 (en) | 2016-09-22 |
| JP6212644B2 (ja) | 2017-10-11 |
| SI3083562T1 (sl) | 2017-11-30 |
| EA201690894A1 (ru) | 2016-10-31 |
| ME02896B (de) | 2018-04-20 |
| CN105793242B (zh) | 2018-02-16 |
| MX2016007566A (es) | 2016-10-03 |
| EP3083562B1 (de) | 2017-09-27 |
| KR101807981B1 (ko) | 2017-12-11 |
| US9776964B2 (en) | 2017-10-03 |
| LT3083562T (lt) | 2018-01-10 |
| EP3083562A1 (de) | 2016-10-26 |
| BR112016011016A8 (pt) | 2018-01-30 |
| DK3083562T3 (da) | 2017-11-13 |
| PL3083562T3 (pl) | 2018-02-28 |
| CY1119583T1 (el) | 2018-03-07 |
| ES2651858T3 (es) | 2018-01-30 |
| AU2014366361B2 (en) | 2017-04-20 |
| WO2015094902A1 (en) | 2015-06-25 |
| CN105793242A (zh) | 2016-07-20 |
| CA2928593A1 (en) | 2015-06-25 |
| EA028921B1 (ru) | 2018-01-31 |